Skip to main content
PRFX
NASDAQ Life Sciences

PainReform Rebrands to PRF Technologies, Signaling Strategic Diversification into AI-Driven Energy and Expanded Healthcare

KI-Analyse von Wiseek
Stimmung info
Positiv
Wichtigkeit info
8
Preis
$1.06
Marktkapitalisierung
$3.207M
52W Tief
$0.611
52W Hoch
$6.65
Market data snapshot near publication time

summarizeZusammenfassung

This name change signifies a major strategic pivot for the company, moving beyond its original single-asset focus to embrace a diversified innovation platform. For a nano-cap company, this redefinition of its core business into areas like AI-driven energy analytics and expanded specialty pharmaceuticals represents a high-stakes attempt to unlock new growth avenues and reduce reliance on a single product. Investors should monitor the execution and progress of these new ventures, as their success will be critical to the company's long-term value creation.


check_boxSchlusselereignisse

  • Corporate Rebranding

    PainReform Ltd. has officially changed its corporate name to PRF Technologies Ltd., effective January 15, 2026, following shareholder approval on January 6, 2026. The Nasdaq ticker symbol will remain PRFX.

  • Strategic Diversification

    The name change reflects a strategic expansion beyond the company's original single-asset focus into diversified healthcare and AI-driven renewable-energy platforms.

  • New Growth Platforms

    The company has established LayerBio, focusing on ophthalmology with OcuRing™-K, and DeepSolar, an AI-driven solar analytics and digital asset-management business.

  • Continued Pharmaceutical Development

    PRF Technologies Ltd. will continue to advance PRF-110, its non-opioid extended-release postoperative pain therapy, alongside its new ventures.


auto_awesomeAnalyse

This name change signifies a major strategic pivot for the company, moving beyond its original single-asset focus to embrace a diversified innovation platform. For a nano-cap company, this redefinition of its core business into areas like AI-driven energy analytics and expanded specialty pharmaceuticals represents a high-stakes attempt to unlock new growth avenues and reduce reliance on a single product. Investors should monitor the execution and progress of these new ventures, as their success will be critical to the company's long-term value creation.

Zum Zeitpunkt dieser Einreichung wurde PRFX bei 1,06 $ gehandelt an der NASDAQ im Sektor Life Sciences, bei einer Marktkapitalisierung von rund 3,2 Mio. $. Die 52-Wochen-Handelsspanne lag zwischen 0,61 $ und 6,65 $. Diese Einreichung wurde mit positiver Marktstimmung und einem Wichtigkeitsscore von 8 von 10 bewertet.

descriptionHaupt-SEC-Einreichung ansehen

show_chartPreisdiagramm

Diesen Artikel teilen

Copied!

feed PRFX - Neueste Einblicke

PRFX
Apr 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
PRFX
Mar 27, 2026, 8:30 AM EDT
Filing Type: 6-K
Importance Score:
8
PRFX
Mar 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
PRFX
Mar 17, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
PRFX
Feb 18, 2026, 9:38 AM EST
Filing Type: 6-K
Importance Score:
8
PRFX
Feb 11, 2026, 8:54 AM EST
Filing Type: 6-K
Importance Score:
8
PRFX
Feb 03, 2026, 4:16 PM EST
Filing Type: 6-K
Importance Score:
8
PRFX
Jan 20, 2026, 9:07 AM EST
Filing Type: 6-K
Importance Score:
7
PRFX
Jan 15, 2026, 4:10 PM EST
Filing Type: 6-K
Importance Score:
8
PRFX
Jan 12, 2026, 9:10 AM EST
Filing Type: 6-K
Importance Score:
7